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Angiotensin II stimulates Pax-2 in rat kidney proximal tubular
cells: Impact on proliferation and apoptosis.
Background. The intrarenal renin-angiotensin system (RAS)
is intimately involved in the tubular cell proliferation, apopto-
sis and regeneration that occur following renal injury. Though
tubular angiotensin II (Ang II) type 2 receptors (AT2R) de-
crease greatly after birth, their number increases after injury.
Notably, during recovery from injury, renal tubular cells dis-
play a relatively immature phenotype expressing genes that
are involved in nephron development, for example, the paired
homeobox-2 gene (Pax-2). The present investigation hypothe-
sized that AT2R activation would stimulate Pax-2 gene expres-
sion in immortalized rat renal proximal tubular cells (IRPTC),
as we have found in fetal cells.
Methods. Pax-2 gene expression in IRPTC was evaluated
by immunofluorescence, Western blot, reverse transcription-
polymerase chain reaction (RT-PCR) with or without Ang II
treatment; apoptosis and proliferation were analyzed by ter-
minal transferase-mediated deoxyuridine triphosphate (dUTP)
nick end-labeling (TUNEL) assay and bromodeoxyuridine
(BrdU) incorporation in stable IRPTC transformants with Pax-
2 sense and antisense orientation, respectively.
Results. Ang II up-regulated Pax-2 gene expression via AT2R
in IRPTC. The stimulatory effect of both Ang II on Pax-2 gene
expression was blocked by PD123319 (AT2R inhibitor), AG
490 (specific Janus kinase 2 (JAK2) inhibitor) and genistein (ty-
rosine kinase inhibitor), but not by losartan (AT1R inhibitor).
Stable transfection of sense Pax-2 cDNA increased, whereas
antisense Pax-2 cDNA down-regulated Pax-2 expression.
Conclusion. Our studies suggest that Ang II stimulates Pax-
2 gene expression in IRPTC via AT2R and the JAK2/signal
transducers and activators of transcription (STAT) signaling
transduction pathway, which may be important in renal repair
following injury. Cells lacking Pax-2 gene expression appear to
be prone toward apoptosis rather than proliferation.
Renal proximal tubular cells (RPTC) are known to
proliferate actively and differentiate in response to kid-
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ney injury. Extensive studies indicated that the intrarenal
renin-angiotensin system (RAS) has a major impact on
tubular cell proliferation, apoptosis and regeneration fol-
lowing kidney injury. As the most active peptide of RAS
family, angiotensin II (Ang II) has at least two types of
receptors that have been identified by techniques of both
pharmacology and molecular biology: the Ang II (type
I) receptor (AT1R) and the Ang II (type II) receptor
(AT2R) [1]. Within the kidney AT1R is the predominant
receptor postnatally, and its functions in the adult kid-
ney have been extensively studied. For example, AT1R
mediates the effect of Ang II on vasoconstriction [2, 3]
and stimulation of sodium and water reabsorption, cell
hypertrophy in the proximal tubules [4–6]. The functions
of AT2R, however, are less well defined. The AT2R is
mainly expressed in fetal tissues and neonatal kidney [7–
9], suggesting that AT2R might play an important role in
renal organogenesis. AT2R expression in the kidney de-
creases after birth [7, 8] and is expressed at only low levels
in the normal adult rat kidney [9–11]. However, AT2R is
reexpressed in proximal tubules after ischemia [12], as it
is in other tissues after injury [13–15], implicating poten-
tial role(s) for AT2R in modulating tissue repair. Indeed,
studies by Zimpelmann and Burns [16] reported that
stable transfection of AT2R in porcine kidney proximal
tubular cells (LLC-PK1) attenuates the mitogenic effect
of epidermal growth factor (EGF) and enhances apopto-
sis. Furthermore, Cao et al [17] have reported that AT2R
is expressed in adult rat kidney proximal tubular cells and
has a role in mediating Ang II–induced proliferation and
apoptosis in proximal tubular cells [17]. Hashimoto et al
[18] recently demonstrated that overexpression of AT2R
in the glomerulus is protective, ameliorating glomerular
hypercellularity and glomerulosclerosis in a mouse rem-
nant kidney model. Taken together, these studies suggest
that AT2R signaling plays an important role in proximal
tubular cell remodeling during renal injury.
Pax-2 belongs to a family of homeobox genes that in-
clude Pax-1 to Pax-9 [19, 20] and contain a paired domain,
which binds to the DNA to initiate transcription of spe-
cific genes. Pax-2 is the first known kidney-specific gene
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Fig. 1. Angiotensin II (Ang II) leads to a biphasic up-regulation of Pax-2 protein and mRNA expression in immortalized renal proximal tubular
cells (IRPTC) as determined by Western blot (A) and reverse transcription-polyymerase chain reaction (RT-PCR) (B). The upper panel shows
representative blots; the lower panel presents quantification by densitometry. Cells were incubated in 5 mmol/L D-glucose Dulbecco’s modified
Eagle’s medium (DMEM) containing 1% depleted fetal bovine serum (dFBS) with or without Ang II (10−11 mol/L to 10−7 mol/L) for 15 minutes
or 30 minutes. Pax-2 expression was assessed by either Western blot or RT-PCR. Membranes were reblotted for b-actin, and relative densities of
Pax-2 were normalized to b-actin. The normalized Pax-2 level in cells incubated in 5 mmol/L glucose was considered the control (100%). Each
point represents the mean ± SD of three independent experiments. ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.005.
to be expressed in the pronephros of the mouse embryo,
and Pax-2 is indispensable for ureteric bud development
[21, 22]. Although Pax-2 is not detected in mature kidneys
at the completion of nephrogenesis [23], it has been re-
ported that Pax-2 is reexpressed in mouse proximal tubu-
lar cells that have been damaged by renal toxins [24].
Recent studies by Maeshima et al [25] also reported that
while Pax-2 is not expressed in normal proximal tubular
cells, its expression is up-regulated in proximal tubular
cells during regeneration after renal ischemia. Such stud-
ies suggest that Pax-2 may participate in cell proliferation
and differentiation as well as in tubular regeneration and
repair after injury in adult kidneys.
We have recently reported that Ang II up-regulates
Pax-2 expression in mouse late embryonic mesenchymal
epithelial cells (MK4) via AT2R but not in mouse early
embryonic mesenchymal fibroblasts (MK3) [26], suggest-
ing that there is a functional relationship between AT2R
and Pax-2 expression during kidney organogenesis. In the
present study, we asked whether a link might also ex-
ist between the RAS and Pax-2 in adult renal proximal
tubular cells, which, if present, might potentially influence
renal regeneration. We employed an in vitro approach
using adult rat immortalized renal proximal tubular cells
(IRPTC) in culture. Our results, as in fetal cells and
metanephroi, indicate that Ang II up-regulates Pax-2
gene expression in IRPTC via the AT2R, an effect that
appears, at least in part, to take place via the Janus kinase
2 (JAK2)/signal transducers and activators of transcrip-
tion (STAT) signaling transduction pathway. Our data
suggest that cells lacking Pax-2 gene expression are more
likely to enter apoptosis than proliferation. We speculate
that the observed up-regulation of Pax-2 gene expression
by Ang II via AT2R might play an important role in renal
regeneration.
METHODS
AG490 (a specific inhibitor of JAK2) and genistein
(an inhibitor of tyrosine kinase) all were purchased from
Biomol Research Laboratories, Inc. (Plymouth Meet-
ing, PA, USA). Oligonucleotides were synthesized by the
DNA Synthesis Core Facility at Massachusetts General
Hospital, Boston, Massachusetts. The In Situ Cell Death
Detection kit was purchased from Roche (Indianapolis,
IN, USA). Bromodeoxyuridine (BrdU) (Sigma Chemi-
cal Co., St. Louis, MO, USA) labeling was detected im-
munohistochemically by the Zymed BrdU staining kit
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Fig. 2. Angiotensin II (Ang II) up-regulates
Pax-2 expression in a time-dependent man-
ner. (A) As analyzed by Western blot, cells
were incubated in 5 mmol/L D-glucose Dul-
becco’s modified Eagle’s medium (DMEM)
containing 1% depleted fetal bovine serum
(dFBS) with or without Ang II at concentra-
tion of 10−9 mol/L for periods of 5 minutes
to 60 minutes. The relative densities of Pax-
2 were compared with b-actin. The normal-
ized Pax-2 level in cells incubated in 5 mmol/L
glucose was considered the control (100%).
Each point represents the mean ± SD of three
independent experiments. ∗P ≤ 0.05; ∗∗P ≤
0.01; ∗∗∗P ≤ 0.005. (B) The immunofluores-
cence staining of Pax-2 in immortalized re-
nal proximal tubular cells (IRPTC) (original
magnification ×400). Cells were incubated in
5 mmol/L D-glucose DMEM containing 1%
dFBS for 15 minutes without or with Ang II
stimulation at concentration 10−9 mol/L. As
a control, cells were incubated with 5% nor-
mal rabbit serum-phosphate-buffered saline
(PBS).
(San Francisco, CA, USA). Mouse anti-b-actin mono-
clonal antibody (clone AC-15) was purchased from Sigma
Chemical Co. A polyclonal anti-Pax-2 antibody was pur-
chased from Covance (Richmond, CA, USA). Polyclonal
antiphospho-JAK2 and anti-JAK2 antibodies were pur-
chased from Upstate Biotechnology (Lake Placid, NY,
USA). The plasmid, pcDNA 3.1/Pax-2 was the kind gift
provided by Dr. Paul Goodyer (McGill University, Mon-
treal, Canada).
Culture of IRPTC
IRPTC, line 93-p-2-1, passages 12 to 18 were used in
the present studies [27]. Characteristics of two lines of
IRPTC developed in our laboratory have been previously
been described [27, 28]. Line 93-p-2-1 is highly differen-
tiated, expressing RPTC characteristics as defined by the
presence of proximal tubular antigens [27]. Thus, IRPTC
resemble primary cultures of RPTCs in vivo. However, in
contrast to primary cultures of rat RPTCs, which cannot
be passaged more than two to three times, IRPTC grow
continuously, with a population doubling time of 16 to
18 hours. By Northern blot [27] and Western blot, both
AT1R and AT2R are present in IRPTC.
IRPTC were grown in 100 × 20 mm plastic Petri dishes
(Fisher, Inc., Pittsburgh, PA, USA) in normal glucose (5
mmol/L) Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen, Inc., Carlsbad, CA, USA), supplemented
with 5% fetal bovine serum (FBS), 100 U/mL of peni-
cillin, and 100 lg/mL of streptomycin. Prior to experi-
ments, cells were synchronized overnight in serum-free
medium. Then, cells were incubated in media containing
normal glucose DMEM plus 1% depleted FBS (dFBS) in
the absence or presence of various concentrations of Ang
II (10−11 mol/L to 10−7 mol/L) and in different incubation
period.
dFBS, depleted of endogenous steroid and thyroid hor-
mones, was prepared by incubation with 1% activated
charcoal and 1% AG 1 × 8 ion-exchange resin (Bio-
Rad Laboratories, Inc., Richmond, CA, USA) for 16 to
24 hours at room temperature, as described by Samuels,
Standby, and Shapiro [29].
Stable gene transfection in IRPTC
IRPTC were plated in 6-well plates at a density of
1–2 × 105 cells/well and incubated overnight in nor-
mal glucose (5 mmol/L) DMEM containing 5% FBS.
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Fig. 3. The effect of losartan and PD123319 on Pax-2 expression as stimulated by angiotensin II (Ang II) in immortalized renal proximal tubular cells
(IRPTC) analyzed by Western blot (A) and reverse transcription-polymerase chain reaction (RT-PCR) (B). The left panel shows representative
blots, and the right panel shows densitometry. Cells were preincubated in 5 mmol/L D-glucose Dulbecco’s modified Eagle’s medium (DMEM)
containing 1% depleted fetal bovine serum (dFBS) for 10 minutess in the absence or presence of losartan (1 × 10−6 mol/L) and PD123319 (1 ×
10−6 mol/L), then incubated with or without Ang II (10−9 mol/L) for 15 minutes or 30 minutes for Pax-2 expression analyzed by Western blot and
RT-PCR, respectively. The relative densities of the Pax-2 were normalized to the b-actin on the same membrane. The normalized Pax-2 level in
cells incubated in 5 mmol/L glucose was considered the control (100%). Each point represents the mean ± SD of three independent experiments.
∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.005.
The sense pcDNA 3.1/Pax-2 (+) was kind gift from
Dr. Paul Goodyer. We constructed the antisense Pax-2
cDNA plasmid ourselves. In brief, the antisense Pax-2
cDNA plasmid was obtained by recloning the human
Pax-2 cDNA from the sense pcDNA3.1(+)/(KpnI/XbaI)
site to pcDNA(−) 3.1/(XbaI/KpnI) site. Those plasmids
were stably transfected into IRPTC using lipofectamine
reagents (Invitrogen, Inc.). The stable transformants
were selected in the presence of geneticin [G418 (500
ug/mL)] (Invitrogen, Inc.) as described previously [30].
Immunofluorescence studies
IRPTC were grown on two-chamber cover slides to
70% to 80% confluence and synchronized with serum-
free medium overnight. Then, cells were incubated with
or without Ang II (10−9 mol/L) for 15 minutes. Cells were
washed, fixed with 4% paraformaldehyde/phosphate-
buffered saline (PBS) for 20 minutes, followed by gentle
washing three times with PBS containing 0.5% bovine
serum albumin (BSA). Then, the cells were permeabi-
lized with PBS containing 0.1% (vol/vol) Triton X-100
and 0.5% BSA for 15 minutes followed by gentle wash-
ing three times as before. Cells were then incubated
with a primary antibody at 4◦C overnight. A fluores-
cein isothiocyanate (FITC)-labeled goat antirabbit lgG
as the secondary antibody was employed (1 hour incu-
bation at room temperature). Immunofluorescence im-
ages were recorded with a Wild MPS 46/52 Photoautomat
(Heerbrugg, Wild Leitz Ltd., Switzerland). For immuno-
histochemical controls, the primary antibody was re-
placed with 5% normal rabbit serum-PBS, which did not
show positive staining, confirming specificity.
Western blotting
Western blot was performed as in previous studies
[6, 30]. Briefly, cells were lysed with 700 uL of lysis
buffer [50 mmol/L Tris-HCl, pH 8.0, containing 1% NP-
40, 250 mmol/L NaCl, 2 mmol/L ethylenediaminete-
traacetic acid (EDTA), 1 mmol/L phenylmethylsulfonyl
fluoride (PMSF), 10 lg/mL leupeptin, 10 lg/mL apro-
tinin, 1 mmol/L sodium orthovanadate, and 50 mmol/L
NaF]. Then, the lysates were sonicated for 30 sec-
onds, heated at 95◦C for 5 minutes, and finally cen-
trifuged at 12,000g for 10 minutes at 4◦C. The protein
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Fig. 4. The effect of PD123319, AG490, and genistein on Pax-2 expression as stimulated by angiotensin II (Ang II) in mouse late embryonic
mesenchymal epithelial cells (MK4) analyzed by Western Blot (A) and reverse transcription-polymerase chain reaction (RT-PCR) (B), respectively.
The left panel shows representative blots, while the right panel shows quantitation of all experiments. Cells were preincubated in 5 mmol/L D-glucose
Dulbecco’s modified Eagle’s medium (DMEM) containing 1% depleted fetal bovine serum (dFBS) for 10 minutes in the absence or presence of
PD123319 (10−6 mol/L), AG490 (10−6 mol/L), and genistein (10−6 mol/L), then incubated with or without Ang II (10−9 mol/L) for 15 minutes or
30 minutes, subsequently lysed and assayed by Western blot or RT-PCR for Pax-2, respectively. Each membrane was reblotted for b-actin. The
relative densities of Pax-2 were compared with b-actin. The normalized Pax-2 level in cells incubated in 5 mmol/L glucose was considered the
control (100%). Each point represents the mean ± SD of three independent experiments. ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.005.
concentrations were measured by the Bradford method
(Bio-Rad). Small aliquots (20 to 50 lL) of super-
natant were subjected to 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
then transferred onto a polyvinylidine difluoride (PVDF)
membrane (Hybond-P) (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). The membrane was first blotted
for anti-Pax-2, phospho-JAK2 antibody and then reblot-
ted for b-actin and JAK2 antibody, respectively. The rel-
ative densities of the Pax-2 and b-actin bands were mea-
sured by computerized laser densitometry.
Reverse transcription-polymerase chain reaction
(RT-PCR) for Pax-2 mRNA
Total RNA was prepared from cultured cells accord-
ing to the manufacturer’s protocol using Trizol (Invit-
rogen). First-strand cDNA was synthesized with the
Super-Script preamplification system (Invitrogen). The
forward primer 5′-TTTGTGAACGGCCGGCCCCTA-
3′, and the reverse primer 5′-CATTGTCACAGATGCC
CTCGG-3′, corresponding to the nucleotide sequences
N+622 to N+642 and N+902 to N+922 of Pax-2 cDNA
[31] were employed for PCR. Primers specific for rat b-
actin [32] (forward and reverse primers 5′-ATG CCA
TCC TGC GTC TGG ACC TGG C-3′ and 5′-AGC ATT
TGC GGT GCA CGA TGG AGG G-3′, correspond-
ing to the nucleotide sequences N+155 to N+179 of
exon 3 and N+115 to N+139 of exon 5 of rat b-actin),
were used for PCR as internal controls. The amplifica-
tion cycles were 20 seconds at 94◦C, 20 seconds at 58◦C,
and 60 seconds at 72◦C for 35 cycles using Rapid Cy-
cler (Idaho Technology, Salt Lake City, UT, USA). The
plasmid, pcDNA 3.1/Pax-2 cDNA, was used as positive
control.
To identify Pax-2 and b-actin cDNA fragments, 15 lL
of the PCR product was subjected to electrophoresis on
1.5% agarose gel and transferred to a Hybond XL ny-
lon membrane (Amersham Pharmacia Biotech). Digox-
igenin (DIG)-labeled oligonucleotides, 5′-CCTGGGCA
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Fig. 5. Angiotensin II (Ang II) stimulates the phosphorylation of JAK2 in a dose-dependent (A) and time-dependent (B) manner in immortalized
renal proximal tubular cells (IRPTC) as analyzed by Western blot. Representative blots are shown in the upper panel, while corresponding
quantitation is shown in the lower panels. (A) Cells were incubated in 5 mmol/L D-glucose Dulbecco’s modified Eagle’s medium (DMEM)
containing 1% depleted fetal bovine serum (dFBS) for 15 minutes with or without Ang II at a concentration range of 10−11 mol/L to 10−7 mol/L.
(B) Cells were incubated in 5 mmol/L D-glucose DMEM containing 1% dFBS for various time period (5 minutes to 60 minutes) in the presence
of Ang II (10−9 mol/L). Cells were then lysed and assayed by Western blot for the phosphorylation of JAK2. The same membrane was reblotted
for total JAK2. Cells incubated in 5 mmol/L glucose medium were considered controls (100%). Each point represents the mean ± SD of three
independent experiments. ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.005.
GGTACTACGAGACCGG-3′, and 5′-TCCTGTGGCA
TCCATGAAACTACATTC-3′ corresponding to nu-
cleotide N+747 to N+760 of Pax-2 cDNA, and nucleotide
N+9 to N+35 of exon 4 of rat b-actin cDNA [32], re-
spectively, (La Roche Biochemicals, Inc., Indianapolis,
IN, USA), were used to hybridize the PCR products on
the membrane. After stringent washing, specific bands
were detected with a DIG luminescent detection kit (La
Roche Biochemicals, Inc.) and exposed to Kodak BMR
film (Amersham Pharmacia Biotech). Pax-2 mRNA lev-
els were normalized by corresponding -actin mRNA lev-
els.
Terminal transferase-mediated deoxyuridine
triphosphate (dUTP) nick end-labeling (TUNEL) assay
Apoptosis was determined with the in situ TUNEL as-
say, using the In Situ Cell Death Detection kit (La Roche
Biochemicals, Inc.). Cells grown on 12 mm glass chamber
slides and rendered quiescent for 24 hours were incubated
in serum-free DMEM for an additional 48 hours without
changing medium until assay. For quantitation of apopto-
sis, the total number of cells was counted and presented
in 10 separate microscopic fields at both 10× and 20×
magnification, with the scorer blinded to the origin of the
slides.
BrdU labeling
Cells grown on 12 mm glass chamber slides and ren-
dered quiescent for 24 hours were incubated in serum-
free DMEM for an additional 48 hours without chang-
ing medium. During the last 21/2 hours in culture,
BrdU (1 mg/mL) was added, and incorporated label
was detected immunohistochemically by commercial kit
(Zymed BrdU staining kit). The percentages of BrdU-
positive nuclei and the proliferation location were calcu-
lated and analyzed in 10 separate microscopic fields at
both 10× and 20× magnification, with the scorer blinded
to the origin of the slides.
Statistical analysis
Three to four separate experiments were performed
for each protocol. The data were subjected to t test or
analysis of variance (ANOVA) followed by Bonferroni
correction to compare the control and treatment groups
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B Fig. 6. The effect of PD123319, AG490, and
genistein on phosphorylation of JAK2 stim-
ulation by angiotensin II (Ang II) in immor-
talized renal proximal tubular cells (IRPTC)
as analyzed by Western blot. (A) A repre-
sentative blot. (B) Quantitation of all ex-
periments. Cells were preincubated in 5
mmol/L D-glucose Dulbecco’s modified Ea-
gle’s medium (DMEM) containing 1% de-
pleted fetal bovine serum (dFBS) for 10 min-
utes in the absence or presence of PD123319
(10−6 mol/L), AG490 (10−6 mol/L), and genis-
tein (10−6 mol/L), then stimulated with or
without Ang II (10−9 mol/L) for 15 minutes
and subsequently lysed and assayed by West-
ern blot for the phosphorylation of JAK2. The
same membrane was reblotted for total JAK2.
Cells incubated in 5 mmol/L glucose medium
were considered controls (100%). Each point
represents the mean ± SD of three inde-
pendent experiments. ∗P ≤ 0.05; ∗∗P ≤ 0.01;
∗∗∗P ≤ 0.005.
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Fig. 7. Pax-2 expression in stable transformants with sense or anti-
sense human Pax-2 cDNA, respectively, analyzed by Western blot. The
plasmids, pcDNA 3.1/Pax-2 (+) and pcDNA 3.1/Pax-2 (−) containing
the human Pax-2 cDNA in sense and antisense orientation were stably
transfected into immortalized renal proximal tubular cells (IRPTC) us-
ing lipofectamine reagents, respectively, selected clones by G418. Non-
transfected IRPTC cells were considered controls.
in the same experiment. A probability level of P ≤ 0.05
was considered statistically significant.
RESULTS
Ang II stimulates Pax-2 expression in IRPTC in
a dose- and time-dependent manner
Ang II (10−11 mol/L to 10−7 mol/L) stimulated Pax-2
gene expression in a dose-dependent manner in IRPTC,
as shown by Western blot (Fig. 1A) and RT-PCR
(Fig. 1B). A maximal response to Ang II occurred at
10−9 mol/L; accordingly, we used Ang II 10−9 mol/L
for the remainder of our experiments. Furthermore,
Ang II at 10−9 mol/L stimulated Pax-2 expression in a
time-dependent manner starting from 5 minutes post-
exposure, reaching a plateau at 15 minutes, this effect
then gradually disappearing, as shown in Figure 2A. We
used the 15-minute time point for all subsequent studies.
Pax-2 immunostaining in IRPTC
Immunofluorescence data indicates a low basal level
of Pax-2 in IRPTC, which was upregulated by Ang II
(10−9 mol/L), as shown in Figure 2B. Immunostaining
appeared intranuclear, consistent with the fact that Pax-
2 is a nuclear transcription factor [31, 33].
PD123319 blocks the stimulatory effect of Ang II
on Pax-2 gene expression in IRPTC
Results with Western blot (Fig. 3A) and RT-PCR
(Fig. 3B) both indicate that PD123319 [an AT2R antag-
onist (10−6 mol/L)] blocks the stimulatory effect of Ang
II on Pax-2 expression in IRPTC, whereas losartan [an
AT1R antagonist (10−6 mol/L)] has no effect. No ad-
ditional inhibitory effects occur when both AT2R and
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Fig. 8. Apoptosis in immortalized renal
proximal tubular cells (IRPTC) stable trans-
formants analyzed by terminal transferase-
mediated deoxyuridine triphosphate (dUTP)
nick end-labeling (TUNEL) staining. (A and
D) pcDNA3.1/hPax-2 (−) sense transfor-
mants. (B and E) Nontransfected IRPTC. (C
and F) pcDNA3.1/hPax-2 (+) antisense trans-
formants. Cells grown on 12 mm glass cover-
slips and rendered quiescent for 24 hours were
incubated in serum-free Dulbecco’s modified
Eagle’s medium (DMEM) for an additional 48
hours without change medium and ready for
assay. For quantitation of apoptosis, the total
number of cells was counted and presented in
10 separate microscopic fields at both ×10 (A,
B, and C) and ×20 (D, E, and F) magnifica-
tion, with the viewer blinded to the origin of
the slides.
Fig. 9. Bromodeoxyuridine (BrdU) labeling
in immortalized renal proximal tubular cells
(IRPTC) stable transformants. (A and D)
pcDNA3.1/hPax-2 (−) sense transformants.
(B and E) Nontransfected IRPTC. (C and
F) pcDNA3.1/hPax-2 (+) antisense transfor-
mants. Cells grown on 12 mm glass coverslips
and rendered quiescent for 24 hours were in-
cubated in serum-free Dulbecco’s modified
Eagle’s medium (DMEM) for an additional
48 hours without change medium. During
the last 21/2 hours culture period, BrdU (1
mg/mL) was added and incorporated label
was detected immunohistochemically by com-
mercial kit. The percentages of BrdU-positive
nuclei and the proliferation location will be
calculated and analyzed in 10 separate micro-
scopic fields at both×10 (A, B, and C) and×20
(D, E, and F) magnification, with the viewer
blinded to the origin of the slides.
AT1R blockers were used simultaneously, as compared
to AT2R blocker alone. These data indicate that the Ang
II effect on Pax-2 expression is mediated via the AT2R,
not the AT1R in IRPTC.
PD123319, AG490, and genistein block the stimulatory
effect of Ang II and on Pax-2 gene expression in IRPTC
We also observed, in addition to blockade by
PD123319, that AG490 (a specific inhibitor of JAK2) and
genistein (an inhibitor of tyrosine kinase) could block the
stimulatory effect of Ang II on Pax-2 gene expression, as
shown by Western blot (Fig. 4A) and RT-PCR (Fig. 4B)
in IRPTC. Moreover, these blockers, by themselves, had
no effect on Pax-2 expression (data not shown).
Ang II stimulates JAK2/STAT phosphorylation
in IRPTC
Western blot analysis indicates that Ang II stimu-
lates the phosphorylation of JAK2 in dose-dependent
(Fig. 5A) and time-dependent manner (Fig. 5B) in
IRPTC. This stimulatory effect of Ang II on JAK2 phos-
phorylation could be blocked by PD123319, AG 490 and
genistein (Fig. 6). These data demonstrated that Ang II
up-regulates Pax-2 gene expression via the JAK2/STAT
signal transduction pathway.
Studies blocking the p38 mitogen-activated protein
kinase (MAPK), p44/42 MAPK and reactive oxygen
species (ROS) pathways revealed did not prevent up-
regulation of Pax-2 by Ang II (data not shown).
Pax-2 protein expression in Pax-2 stable transformants
Figure 7 shows that Pax-2 expression is up-regulated
or down-regulated in IRPTC that have been stably trans-
fected with Pax-2 sense and antisense cDNA, respec-
tively, as compared to controls (nontransfected cells). As
expected, cells stably transfected with Pax-2 sense trans-
formants overexpress Pax-2, whereas stably transfected
with Pax-2 antisense transformants express less Pax-2
as compared with control. These transformed cells were
used for further studies that included cell proliferation
and apoptosis.
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Fig. 10. Quantitation of bromodeoxyruidine (BrdU) and terminal
transferase-mediated deoxyuridine triphosphate (dUTP) nick end-
labeling (TUNEL) staining in Pax-2 transformants. The y-axis shows
the percentage of BrdU-, TUNEL-positive cells comparing to control
(100%). () control; () Pax-2 sense transformants; ( ) Pax-2 antisense
transformants. ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.005.
Cell proliferation and apoposis in IRPTC stable
transformants
BrdU labeling and in situ TUNEL assay indicated that
more cell proliferation and less apoptosis occur in Pax-
2 sense transformants as compared to Pax-2 antisense
transformants and controls (Figs. 8 and 9). Figure 10
shows quantitation of these studies. In Pax-2 sense trans-
formants, the percentage of BrdU-positive cells was more
than twofold higher than control (210.8 ± 19.8% vs. 100 ±
15.3%) (P ≤ 0.01), and the percentage of apoptotic cells
was decreased as compared to controls (30.6 ± 15.3% vs.
100 ± 12.3%) (P ≤ 0.05), respectively. In contrast, Pax-2
antisense transformants exhibited a decreased the per-
centage of BrdU-positive (45.6 ± 10.3% vs. 100 ± 15.3%)
(P ≤ 0.05) and an increased percentage of apoptotic cells
comparing to control (240.6 ± 20.3% vs. 100 ± 12.3%)
(P ≤ 0.005), respectively. These data indicated that cells
lacking Pax-2 gene expression are prone toward apopto-
sis rather than proliferation.
DISCUSSION
The present in vitro studies indicate that Ang II, a ma-
jor effector of the RAS, regulates Pax-2 gene expression
in young adult rat RPTCs via AT2R. These findings may
have substantial implications for cell regeneration fol-
lowing kidney injury, as Pax genes and the RAS both are
proven to be critically important for renal cell prolifera-
tion and apoptosis.
Pax-2, a transcription factor belonging to the Pax fam-
ily, plays a key regulatory role during renal organogenesis
[34]. During renal development Pax-2 is detected specif-
ically in the caudal mesonephric duct, ureteric bud, and
later in mesenchymal condensates induced by the ureteric
bud [35–37]. Later during the process of nephrogenesis,
Pax-2 is restricted to the distal part of the S-shaped body,
and its expression is extinguished as cells differentiate
[20]. Pax-2 is likely a master gene essential for controlling
tubular cell proliferation and differentiation [25], medi-
ating mesenchymal-to-epithelial transformation as well
as apoptosis [38].
Without a functional Pax-2 gene, renal agenesis occurs
[34, 39–42]. Dysregulated Pax-2 expression has been as-
sociated with developmental renal abnormalities in mice
[35, 43] and humans [40, 44]. Pax-2 is the first known
kidney-specific gene to be expressed in the pronephros of
the mouse embryo, and Pax-2 is indispensable for ureteric
bud development [21, 22]. Homozygous null Pax-2 mice
fail to form any kidneys, ureters and genital tracts [35]. In
humans and mice, heterozygous Pax-2 mutations cause
kidney, eye, and central nervous system abnormalities,
constituting a syndrome called renal-coloboma syndrome
(RCS) [43, 45]. Once nephrogenesis is completed, Pax-
2 is down-regulated and not normally detected in the
mature mammalian kidney [23]. However, Pax-2 is ex-
pressed in response to renal injury, at a point at which
numerous tubular cells also display immature pheno-
type and express vimentin (a mesenchymal marker) [24,
25, 35, 46]. Recent studies revealed that Pax-2 is reex-
pressed in tubular cells damaged by renal toxins [24] and
ischemia [25]. Pax-2 is expressed during tubular regen-
eration, along with the mesenchymal marker, vimentin,
suggesting that the regenerating cells have characteristics
of immature progenitor-like tubular cells [24–25]. Pax-2
has been shown to act as a transcriptional factor, inhibit-
ing cell apoptosis or promoting cell survival in a mouse
inner medullary collecting duct cell line (mIMCD) [47].
Taken together, these studies raise the possibility that
Pax-2 is a critical gene in controlling cell proliferation and
differentiation during post-injury kidney regeneration.
The signaling molecule(s) that regulate(s) Pax-2 ex-
pression in the kidney is relatively unknown. It has been
reported that EGF increased the half-life of Pax-2 pro-
tein in a rat kidney epithelial cell line (NRK-52E) [48],
whereas transforming growth factor-b (TGF-b1) [49] and
activin A [25], a member of the TGF-b superfamily down-
regulate Pax-2 expression in proximal tubular cells. We
recently reported that Ang II stimulates Pax-2 protein
and Pax-2 mRNA expression in mouse late mesenchy-
mal epithelial cells (MK4) but not in early mesenchymal
fibroblasts (MK3) [26], suggesting that RAS and Pax-
2 interactions may be important in renal development.
We therefore hypothesized that Ang II might be capable
of influencing Pax-2 expression in adult kidney proximal
tubular cells, which, if true, might have important impli-
cations for further understanding of tubular regeneration
after injury.
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We observed that Ang II at physiological concentra-
tion (10−9 mol/L) [50] stimulated Pax-2 gene expression
in IRPTC by more than twofold as compared to control
(Figs. 1 and 2). This effect occurred rapidly. It is possi-
ble that the stimulatory effect of Ang II on Pax-2 protein
seen within 5 minutes might be mediated via phosphory-
lation. Such a phenomenon would not need to change
the pattern of Pax-2 nuclear staining as shown in our
Figure 2B. Indeed, Cai Y et al [51] demonstrated that
Pax2 is phosphorylated by the c-Jun N-terminal kinase
(JNK) to enhance Pax2-dependent transcription, but not
the ERK1/2 or p38 MAPKs in 293 cells. Unfortunately,
due to the lack of commercially available specific anti-
bodies against phosphorylated Pax-2 protein, we could
not perform experiments to look more directly at this
possibility.
Several studies have demonstrated that AT2R is not
only present in fetal tissue [7] but also in the adult kidney
[17, 52]. AT2R has a range of effects related to kidney
disease, such as regulating the chemokine RANTES [53]
and the matrix protein osteopontin [17], and mediating
effects of the vascular kinin system [54], nitric oxide re-
lease [55], and prostaglandin E2 production [56]. There-
fore, the AT2 receptor could have effects on a range of
pathophysiologic processes implicated in progressive re-
nal injury. However, the specific role of AT2R in the evo-
lution and repair of kidney injury is largely unknown.
In our present studies, an AT2R antagonist (PD123319),
but not an AT1R antagonist (losartan), blocked the stim-
ulatory effect of Ang II on Pax-2 and Pax-2 mRNA ex-
pression in IRPTC (Fig. 3), suggesting that Ang II up-
regulates Pax-2 expression via AT2R and not AT1R.
Furthermore, studies we performed to test whether p38
MAPK, p44/42 MAPK and ROS generation were in-
volved in Ang II up-regulation of Pax-2 in IRPTC were
negative.
Recent reports suggest that modulation or activation
of JAK/STAT pathway by Ang II has pathologic conse-
quences for cardiovascular [57] and renal [58] function.
JAK/STAT pathways are activated by multistep phospho-
rylation cascades after ligand-cell surface receptor bind-
ing which lead directly to target gene promoters in the
nucleus, providing mechanisms for transcriptional regu-
lation without second messengers. JAK kinases, once acti-
vated, selectively phosphorylate STATs (STAT1, STAT2,
STAT3, STAT4, STAT5A/B, and STAT6), that form
homo- and heterodimers, rapidly translocating to the nu-
cleus and bind to the “regulatory element” in the pro-
moter of relevant gene [59]. The apparent interaction of
Ang II and Pax-2 in our present studies may suggest that
Ang II phosphorylates components of the JAK/STAT
pathway, which in turn affects Pax-2 gene expression in
vitro. Our data indicate that AG490 and genistein blocked
the Ang II up-regulation of Pax-2 gene expression in
IRPTC (Fig. 4). Furthermore, Ang II stimulated the phos-
phorylation of JAK2 in IRPTC (Fig. 5). Since this stim-
ulatory effect of Ang II could be blocked by PD123319,
AG490 and genistein in IRPTC (Fig. 6), it appears that
Ang II likely upregulates Pax-2 gene expression via the
JAK2/STAT signal transduction pathway.
We examined stable transformants of Pax-2 cDNA in
sense and antisense orientation to enhance or attenuate
the basal Pax-2 expression in IRPTC (Fig. 7). More apop-
tosis and less proliferation were observed in IRPTC an-
tisense Pax-2 cDNA transformants (Figs. 8, 9, and 10).
Thus, IRPTC lacking Pax-2 gene expression are prone to
apoptosis as opposed to proliferation. These observations
agree with those of Gnarra and Dressler [60], who found
that Pax-2 gene function is required for proliferation, as
well as differentiation in a renal cell carcinoma (RCC) cell
line generally thought to arise from the epithelium of the
proximal tubules. These observations agree in part with
Torban et al [36, 47] who reported that lacking of Pax-2
gene expression greatly increases cell apoptosis without
effect on proliferation rate in cultured murine collect-
ing duct cells (mIMCD-3) and human embryonic kidney
cells (HEK-293). Thus, Pax-2 appears to be associated
with cell survival, protects against cell apoptosis, but in-
creases cell proliferation, depending on the different cell
type response.
While the mechanism by which Pax-2 influences the
apoptotic cascade in IRPTC cells has not been delineated,
it has been suggested that Pax-2 has a protective effect on
caspase-2–induced apoptosis in HEK-293 cells [36, 47].
Pax-2 inhibits transcription of p53, a pivotal molecule
regulating entry into the final common apoptotic path-
way [61, 62]. Moreover, AT2R promotes cellular prolif-
eration and apoptosis in proximal tubular cells, perhaps
through generation of TGF-b , and then triggering the
expression of proapoptotic genes such as Fas, FasL or
Bax [63]; modulation of heme oxygenase (HO-1) expres-
sion [63–64]; formation of nitric oxide [49]; inactivation of
Egr-1 activity [18]; or activation of the osteopontin gene
[17].
Our studies would suggest that the stimulatory effect
of Ang II on Pax-2 gene expression in rat RPTCs is me-
diated, at least in part, via the AT2R and JAK2/STAT
signaling transduction pathway; cells lacking Pax-2 gene
expression are prone toward apoptosis rather than pro-
liferation in IRPTC. Take together, our data suggest that
RAS and Pax-2 interactions that may be important in
renal repair following injury.
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